Concepedia

The Proton Pump Inhibitor, Omeprazole, but Not Lansoprazole or Pantoprazole, Is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration with Clopidogrel

Brian W. Ogilvie, Phyllis Yerino, Faraz Kazmi, David B. Buckley, Amin Rostami‐Hodjegan, Brandy L. Paris, Paul Toren, Andrew Parkinson

Drug Metabolism and Disposition · 2011 · 110 citations · 36 references

DOI

Concepts

References

36

Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome

P. Michael Ho · JAMA · 2009 · 1K citations

, , +14

Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite

Miho Kazui, Yumi Nishiya, Tomoko Ishizuka et al. · Drug Metabolism and Disposition · 2009 · 821 citations

, , +17

COMPARISON OF INHIBITORY EFFECTS OF THE PROTON PUMP-INHIBITING DRUGS OMEPRAZOLE, ESOMEPRAZOLE, LANSOPRAZOLE, PANTOPRAZOLE, AND RABEPRAZOLE ON HUMAN CYTOCHROME P450 ACTIVITIES

Xueqing Li, Tommy B. Andersson, Marie M. Ahlström et al. · Drug Metabolism and Disposition · 2004 · 642 citations

, , +17

Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement

Dirk Sibbing, Werner Koch, Daniela Gebhard et al. · Circulation · 2010 · 583 citations

, , +17

VALIDATED ASSAYS FOR HUMAN CYTOCHROME P450 ACTIVITIES

Robert L. Walsky, R. Scott Obach · Drug Metabolism and Disposition · 2004 · 504 citations

, , +15